These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 26350201)

  • 1. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
    Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
    Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery.
    Vargas HA; Burger IA; Goldman DA; Miccò M; Sosa RE; Weber W; Chi DS; Hricak H; Sala E
    Eur Radiol; 2015 Nov; 25(11):3348-53. PubMed ID: 25916387
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
    Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
    Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
    Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.
    Hynninen J; Kemppainen J; Lavonius M; Virtanen J; Matomäki J; Oksa S; Carpén O; Grénman S; Seppänen M; Auranen A
    Gynecol Oncol; 2013 Nov; 131(2):389-94. PubMed ID: 23994535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
    Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
    Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
    J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer.
    Fruscio R; Sina F; Dolci C; Signorelli M; Crivellaro C; Dell'Anna T; Cuzzocrea M; Guerra L; Milani R; Messa C
    Gynecol Oncol; 2013 Dec; 131(3):689-93. PubMed ID: 24076062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
    De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
    Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
    Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
    Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study.
    Signorelli M; Guerra L; Pirovano C; Crivellaro C; Fruscio R; Buda A; Cuzzucrea M; Elisei F; Ceppi L; Messa C
    Gynecol Oncol; 2013 Nov; 131(2):395-9. PubMed ID: 23988414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in patients with epithelial ovarian cancer.
    Lee M; Lee H; Cheon GJ; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Eur Radiol; 2017 Jan; 27(1):16-23. PubMed ID: 27121932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of peritoneal metastases with DW-MRI, CT, and FDG PET/CT before cytoreductive surgery for advanced stage epithelial ovarian cancer.
    Mikkelsen MS; Petersen LK; Blaakaer J; Marinovskij E; Rosenkilde M; Andersen G; Bouchelouche K; Iversen LH
    Eur J Surg Oncol; 2021 Aug; 47(8):2134-2141. PubMed ID: 33812768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.
    Shim SH; Lee SJ; Kim SO; Kim SN; Kim DY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2015 Jan; 136(1):30-6. PubMed ID: 25448457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
    Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P
    Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    González García B; García Vicente AM; Jiménez Londoño GA; Pena Pardo FJ; Bellón Guardia ME; Talavera Rubio MP; Palomar Muñoz A; Gómez Herrero P; Soriano Castrejón ÁM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(4):233-240. PubMed ID: 28284928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer.
    Chung HH; Kim JW; Park NH; Song YS; Cheon GJ
    Eur Radiol; 2018 May; 28(5):2107-2114. PubMed ID: 29260365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
    Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.